A Phase II Trial of Pharmacogenetic-Based Dosing of Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy for Advanced Small Bowel Adenocarcinoma
Phase of Trial: Phase II
Latest Information Update: 29 Aug 2017
At a glance
- Drugs Capecitabine (Primary) ; Irinotecan (Primary) ; Oxaliplatin (Primary)
- Indications Intestinal cancer
- Focus Pharmacogenomic; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 25 Jul 2017 Status changed from active, no longer recruiting to completed.
- 22 Jul 2015 Status changed from recruiting to active, no longer recruiting as per ClinicalTrials.gov record.